Helping manufacturers realize biosimilar potential
New coding and payment policy could stifle biosimilar innovation
In November 2015, the Centers for Medicare & Medicaid Services finalized a controversial Medicare payment rule for biosimilars: all biosimilars relative to the same reference product will share the same Healthcare Common Procedure Coding System code and payment rate, separate from the reference product. This creates a single, blended Medicare reimbursement rate for the biosimilars based on the average sales price of all biosimilars to a reference product
Are biosimilars the new generics?
Start a conversation
We’re value drivers and problem solvers. Let us connect you with experts who understand your world and what success demands.